Last reviewed · How we verify
EHT 0202 etazolate
Etazolate is a phosphodiesterase inhibitor.
Etazolate is a phosphodiesterase inhibitor. Used for Anxiety, Hallucinations.
At a glance
| Generic name | EHT 0202 etazolate |
|---|---|
| Also known as | EHT 0202, etazolate |
| Sponsor | Exonhit |
| Drug class | Phosphodiesterase inhibitor |
| Target | Phosphodiesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Etazolate acts by inhibiting the enzyme phosphodiesterase, leading to increased levels of cyclic AMP (cAMP) in the brain, which can help to reduce anxiety and hallucinations.
Approved indications
- Anxiety
- Hallucinations
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |